Erratum: Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: A UK perspective (PharmacoEconomics (2013) 31 (807-822) DOI: 10.1007/s40273-013-0076-z);Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: A UK perspective

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 807-822

  Bentley, Anthony ^a   Gillard, Samantha ^a   Spino, Michael ^b,c   Connelly, John ^b   Tricta, Fernando ^b  

^a Decision Resources Group   (United Kingdom)

^b ApoPharma Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; PHOSPHATE;

AGRANULOCYTOSIS; ARTICLE; BETA THALASSEMIA; CARDIOVASCULAR MORTALITY; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FANCONI RENOTUBULAR SYNDROME; FERRITIN BLOOD LEVEL; HEALTH CARE UTILIZATION; HEPATITIS; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; META ANALYSIS; MORBIDITY; NATIONAL HEALTH SERVICE; NEUTROPENIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL WORK; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED KINGDOM;

BETA-THALASSEMIA; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, ECONOMIC; PYRIDONES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84883495861     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0101-2     Document Type: Erratum

References (70)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480-7. (Pubitemid 351821761)
2. Higgs D, Engel J, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373-83.
3. McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009;13(1)(iii-iv, ix-xi):1-121.
4. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5(11).
5. UK Thalassaemia Society. Standards for the clinical care of children and adults with thalassaemia in the UK [online]. http://sct.screening.nhs.uk/cms. php?folder=2493 [Accessed 19 Feb 2013].
6. Modell B, Khan M, Darlison M, Westwood M, Ingram D, Pennell D. Improved survival of thalassaemia major in the UK and relation to T2&z. ast;cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
7. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Clin Haematol. 1994;7(4):919-40.
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93. (Pubitemid 39390442)
9. Cunningham M, Macklin E, Neufeld E, Cohen A. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34-9. (Pubitemid 38879833)
10. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2. (Pubitemid 30339248)
11. Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30. (Pubitemid 19158169)
12. Novartis Pharmaceuticals. Desferal SPC [online]. http://www.medicines. org.uk/EMC/medicine/2666/SPC/Desferal+Vials%2c+500mg+or+2g/ [Accessed 19 Feb 2013].
13. Abetz L, Baladi J-F, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.
14. Delea T, Edelsberg J, Sofrygin O, Thomas S, Baladi J-F, Phatak P, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-29. (Pubitemid 47438560)
15. European Medicines Agency. Ferriprox: EPAR - product information [online]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000236/human-med-000789.jsp&mid=WC0b01ac058001d124 [Accessed 19 Feb 2013].
16. Borgna-Pignatti C, Cappellini M, De Stefano P, Del Vecchio G, Forni G, Gamberini M, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
17. European Medicines Agency. Exjade: EPAR - Product Information [online]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000670/human-med-000780.jsp&mid=WC0b01ac058001d124 [Accessed 19 Feb 2013].
18. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196-208. (Pubitemid 34743754)
19. Pennell D, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
20. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11:20.
21. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41-7.
22. Kirk P, Roughton M, Porter J, Walker J, Tanner M, Patel J, et al. Cardiac T2&z.ast;magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-8.
23. Pennell D, Carpenter J, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45.
24. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-75.
25. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876- 84. (Pubitemid 46598901)
26. Hoffbrand A, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102(1):17-24. (Pubitemid 36759630)
27. Ceci A, Mangiarini L, Felisi M, Bartoloni F, Ciancio A, Capra M, et al. The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients. Anemia. Epub 2011 Jun 05.
28. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609-21. (Pubitemid 351929059)
29. Karnon J, Tolley K, Vieira J, Chandiwana D. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Clin Drug Investig. 2012;32(12):805-15. doi: 10.1007/s40261-012-0008-2.
30. Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31(7):493-505.
31. Cappellini M, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-62.
32. Cohen A, Glimm E, Porter J. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-7.
33. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241-3. (Pubitemid 44408435)
34. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247-51.
35. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145(2):245-54.
36. Modell B, Letsky E, Flynn D, Peto R, Weatherall D. Survival and desferrioxamine in thalassaemia major. Br Med J. 1982;284(6322):1081-4. (Pubitemid 12135972)
37. Nisbet-Brown E, Olivieri N, Giardina P, Grady R, Neufeld E, Séchaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-602. (Pubitemid 36578996)
38. Piga A, Galanello R, Forni G, Cappellini M, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-80. (Pubitemid 44023139)
39. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330-6. (Pubitemid 34779559)
40. Cohen A, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305-12. (Pubitemid 30143646)
41. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-7. (Pubitemid 37022545)
42. Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol. 2010;85(4):335-44.
43. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96. (Pubitemid 36648438)
44. El Alfy M, Sari T, Lee C, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601-5. doi: 10.1097/MPH.0b013e3181ec0f13.
45. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (2008) [online]. http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 19 Feb 2013].
46. HM Treasury. Green Book: appraisal and evaluation in central government; 2003.
47. Miller D, Homan S. Determining transition probabilities: confusion and suggestions. Med Decis Making. 1994;14(1):52-8. (Pubitemid 24032682)
48. The Institute for Safe Medication Practices. QuarterWatch: 2009 Quarter 4.
49. Apotex Inc. Briefing book for the Ferriprox Advisory Committee [online]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/ucm271469.htm [Accessed 19 Feb 2013].
50. Novartis Pharmaceuticals. Exjade® US Prescribing Information.
51. Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, et al. Acquired proximal renal tubular dysfunction in ß-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32(7):564-7.
52. TUFTS cost-effectiveness analysis registry. https://research.tufts-nemc. org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspx.
53. Ossa D, Briggs A, Tafesse E, Iloeje U, Mukherjee J, Lozano-Ortega G, et al. Impact on quality of life of health states induced by chronic hepatitis B infection: estimates from uninfected and infected persons in the UK. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 8th Annual European Congress, Florence; 2005 Nov 6-8.
54. Perlis R, Ganz D, Avorn J, Schneeweiss S, Glynn R, Smoller J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427-34. (Pubitemid 41368364)
55. Priest V, Begg E, Gardiner S, Frampton C, Gearry R, Barclay M, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. PharmacoEconomics. 2006;24(8):767-81. (Pubitemid 44232105)
56. BMJ Group. British National Formulary 63, London; 2012.
57. Apotex Inc. USA registry for enhanced pharmacovigilance of agranulocytosis in patients treated with Ferriprox®, Toronto; 2013.
58. Curtis L. Unit costs of health and social care 2010. Canterbury: Personal Social Services Research Unit; 2010.
59. Department of Health. NHS Reference costs 2009/10 [online]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123459 [Accessed 19 Feb 2013].
60. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13(8):922-33.
61. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2010;85(2):132-4.
62. Grangé S, Bertrand D, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25(7):2376-8.
63. Rafat C, Fakhouri F, Ribeil J, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54(5):931-4.
64. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674-6.
65. Briggs A, Goeree R, Blackhouse G, O'Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290-308. (Pubitemid 34791317)
66. Briggs AH. Handling uncertainty in cost-effectiveness models. PharmacoEconomics. 2000;17(5):479-500. (Pubitemid 30398806)
67. Pennell D, Porter J, Piga A, Lai Y, El-Beshlawy A, Beloul K, et al. A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β-thalassemia major and iron overload (CORDELIA) [abstract no.2124]. Blood. 2012;120:21.
68. Carpenter J-P, He T, Kirk P, Roughton M, Anderson L, de Noronha S, et al. On T2&z.ast;magnetic resonance and cardiac iron/clinical perspective. Circulation. 2011;123(14):1519-28.
69. Department of Health. 2010-2011: payment by results National Tariff [online]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-112284 [Accessed 19 Feb 2013].
70. County Pathology. Cost of tests [online]. http://www.countypathology.co. uk/Prices/Prices.html [Accessed 19 Feb 2013].